MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

MDT

100.53

-0.59%↓

A

134.71

-0.71%↓

VEEV

218.77

-1.13%↓

HQY

82.13

-1.25%↓

NEOG

10.22

+2.51%↑

Search

IQVIA Holdings Inc

Avatud

SektorTervishoid

240.82 0.93

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

236.29

Max

243.74

Põhinäitajad

By Trading Economics

Sissetulek

66M

332M

Müük

83M

4.1B

P/E

Sektori keskmine

32.889

90.422

Kasumimarginaal

8.098

Töötajad

91,000

EBITDA

102M

883M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+10.76% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

3.3B

41B

Eelmine avamishind

239.89

Eelmine sulgemishind

240.82

Uudiste sentiment

By Acuity

50%

50%

148 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

IQVIA Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. jaan 2026, 23:07 UTC

Tulu

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27. jaan 2026, 21:27 UTC

Tulu

Texas Instruments 4Q Sales Rise, Profit Falls

27. jaan 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27. jaan 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. jaan 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27. jaan 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27. jaan 2026, 23:20 UTC

Tulu

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27. jaan 2026, 23:20 UTC

Tulu

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27. jaan 2026, 23:19 UTC

Tulu

SK Innovation Posts Net Loss for Second Consecutive Year

27. jaan 2026, 23:19 UTC

Tulu

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27. jaan 2026, 23:18 UTC

Tulu

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27. jaan 2026, 23:18 UTC

Tulu

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27. jaan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27. jaan 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27. jaan 2026, 23:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27. jaan 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27. jaan 2026, 22:06 UTC

Tulu

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27. jaan 2026, 21:51 UTC

Tulu

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27. jaan 2026, 21:43 UTC

Tulu

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27. jaan 2026, 21:41 UTC

Tulu

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27. jaan 2026, 21:38 UTC

Tulu

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27. jaan 2026, 21:32 UTC

Tulu

Ampol: Modest Profit From F&I International in 2025

27. jaan 2026, 21:32 UTC

Tulu

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27. jaan 2026, 21:31 UTC

Tulu

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27. jaan 2026, 21:31 UTC

Tulu

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27. jaan 2026, 21:30 UTC

Tulu

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27. jaan 2026, 21:29 UTC

Tulu

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27. jaan 2026, 21:29 UTC

Tulu

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27. jaan 2026, 21:28 UTC

Tulu

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Võrdlus sarnastega

Hinnamuutus

IQVIA Holdings Inc Prognoos

Hinnasiht

By TipRanks

10.76% tõus

12 kuu keskmine prognoos

Keskmine 260.62 USD  10.76%

Kõrge 290 USD

Madal 230 USD

Põhineb 15 Wall Streeti analüütiku instrumendi IQVIA Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

12

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

150.68 / 153.45Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

148 / 352 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat